New interview with CEO Dr. Nina Webster and Pitt Street Research, filmed 18th March.
Points of interest are mentioned include recent results, future trial end points, strong negotiation position due to premium (derisked) CR, fast track approvals (China might be happy with data on hand* no need for full scale trial in China) , 80% of market negations (USA & China.)
Kidney disease sounds like a massive unmet need in China too.
https://youtu.be/ypOTL7r8Bxg?si=3ZnQZQplDhpJ6kPh
DXB Media thread., page-114
-
- There are more pages in this discussion • 61 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add DXB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
54.5¢ |
Change
0.015(2.83%) |
Mkt cap ! $299.6M | |||
| Open | High | Low | Value | Volume |
| 53.0¢ | 54.5¢ | 52.0¢ | $905.8K | 1.698M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 8606 | 53.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 54.5¢ | 72714 | 5 |
View Market Depth
| Last trade - 16.10pm 26/06/2024 (20 minute delay) ? |
| DXB (ASX) Chart |